Skip to main content

18-06-2018 | Rheumatoid arthritis | EULAR 2018 | Video

Expert commentary: Malignancy and infection risk with JAK inhibitors in RA patients

EULAR president Hans Bijlsma comments on a meta-analysis evaluating the risk for malignancy or serious infection among RA patients treated with JAK inhibitors (5:44). 

More on this topic

Repurposing rheumatology drugs for COVID-19

Experts discuss the rationale, data on different agents, and the potential impact on rheumatology practice.

  • » Featuring insights from the COVID-19 Global Rheumatology Alliance, EULAR, and the Lupus Foundation of America
Image Credits